Risk factors for the development of sinusoidal obstruction syndrome after treatment with gemtuzumab ozogamicin
| Variable . | SOS (n = 11) . | Non-SOS (n = 12) . | P . |
|---|---|---|---|
| Sex (M/F) | 3/8 | 6/6 | .40 |
| Age (y) | 43.1 ± 10.9 | 45.4 ± 12.6 | .48 |
| No. patients conditioned with CY + TBI (%) | 3 (27) | 7 (58) | .21 |
| No. patients with a matched sibling graft (%) | 8 (73) | 5 (42) | .21 |
| No. patients who had veno-occlusive disease after transplantation (%) | 4 (36) | 4 (33) | .99 |
| No. patients who had GVHD at any time after transplantation (%) | 9 (82) | 10 (83) | .99 |
| No. patients with active GVHD at the time of gemtuzumab ozogamicin infusion (%) | 4 (40) | 5 (42) | .99 |
| No. patients receiving cyclosporine at time of gemtuzumab ozogamicin infusion (%) | 3 (27) | 3 (25) | .99 |
| Peripheral blood leukocyte count on the day of first gemtuzumab ozogamicin infusion (cells/mm3) | 6863 ± 6165 | 6732 ± 7203 | .99 |
| No. patients with blast cells in peripheral blood within 24 hours of first gemtuzumab ozogamicin infusion | 10/10* | 8/11* | .21 |
| No. blast cells (± SD) in peripheral blood on day of first gemtuzumab ozogamicin infusion (cells/mm3) | 2805 ± 3779 | 2716 ± 6569 | .34 |
| Time between transplantation and first dose of gemtuzumab ozogamicin (d) | 270 ± 281 | 140 ± 98 | .51 |
| No. gemtuzumab ozogamicin doses | 1.4 ± 0.5 | 1.6 ± 0.8 | .62 |
| Total gemtuzumab ozogamicin dose (mg/m2) | 9.4 ± 3.7 | 6.3 ± 5.6 | .09 |
| Variable . | SOS (n = 11) . | Non-SOS (n = 12) . | P . |
|---|---|---|---|
| Sex (M/F) | 3/8 | 6/6 | .40 |
| Age (y) | 43.1 ± 10.9 | 45.4 ± 12.6 | .48 |
| No. patients conditioned with CY + TBI (%) | 3 (27) | 7 (58) | .21 |
| No. patients with a matched sibling graft (%) | 8 (73) | 5 (42) | .21 |
| No. patients who had veno-occlusive disease after transplantation (%) | 4 (36) | 4 (33) | .99 |
| No. patients who had GVHD at any time after transplantation (%) | 9 (82) | 10 (83) | .99 |
| No. patients with active GVHD at the time of gemtuzumab ozogamicin infusion (%) | 4 (40) | 5 (42) | .99 |
| No. patients receiving cyclosporine at time of gemtuzumab ozogamicin infusion (%) | 3 (27) | 3 (25) | .99 |
| Peripheral blood leukocyte count on the day of first gemtuzumab ozogamicin infusion (cells/mm3) | 6863 ± 6165 | 6732 ± 7203 | .99 |
| No. patients with blast cells in peripheral blood within 24 hours of first gemtuzumab ozogamicin infusion | 10/10* | 8/11* | .21 |
| No. blast cells (± SD) in peripheral blood on day of first gemtuzumab ozogamicin infusion (cells/mm3) | 2805 ± 3779 | 2716 ± 6569 | .34 |
| Time between transplantation and first dose of gemtuzumab ozogamicin (d) | 270 ± 281 | 140 ± 98 | .51 |
| No. gemtuzumab ozogamicin doses | 1.4 ± 0.5 | 1.6 ± 0.8 | .62 |
| Total gemtuzumab ozogamicin dose (mg/m2) | 9.4 ± 3.7 | 6.3 ± 5.6 | .09 |
Continuous variables are expressed as mean ± SD.
CY + TBI indicates cyclophosphamide plus total body irradiation.
One patient in each group did not have blood drawn within 24 hours of Mylotarg infusion.